GROENHUYSEN WILHELMUS CM — SEC Form 4 filings
SEC reporting owner CIK 1264783. 6 Form 4 filings on record with FilingPulse; latest filed 2025-05-21.
Transaction summary — filings shown
Covers all 6 filings on record, filed 2024-02-29 to 2025-05-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 5,627 shares, $90,430 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 2,303 shares @ $16.14 ($37,177) in NovoCure Ltd, filed 2024-02-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NovoCure Ltd (NVCR) | Chief Operating Officer | 4 | — | 3 legs · 5,627 sh · $90,430 | 6 |
| OptiNose, Inc. (OPTN) | Director | 2 | — | — | 9 |
Form 4 filings — GROENHUYSEN WILHELMUS CM
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-05-21 | 4 | OptiNose, Inc. (OPTN) | Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 3,566 (derivative) · Disposition to issuer (D): 2,133 (derivative) · Disposition to issuer (D): 962 (derivative) · Disposition to issuer (D): 962 (derivative) · Disposition to issuer (D): 962 (derivative) · +2 more | EDGAR |
| 2024-08-06 | 4 | NovoCure Ltd (NVCR) | Grant/award (A): 1,055 @ $12.24 | EDGAR |
| 2024-06-07 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | NovoCure Ltd (NVCR) | Option exercise (M): 124,373 @ $22.82 · Option exercise (M): 124,373 (derivative) @ $22.82 | EDGAR |
| 2024-03-05 | 4 | NovoCure Ltd (NVCR) | Sale (S): 2,107 @ $16.03 · Sale (S): 1,217 @ $16.01 | EDGAR |
| 2024-02-29 | 4 | NovoCure Ltd (NVCR) | Grant/award (A): 3 @ $12.69 · Grant/award (A): 47,034 @ $16.30 · Sale (S): 2,303 @ $16.14 · Grant/award (A): 71,920 (derivative) @ $16.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1264783 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →